Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Harvard University · Dana-Farber Cancer Institute · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,399
total citations
- FWCI
- 58.08
- Percentile
- 100%
- References
- 35
Citations per year
Authors
24- GDGeorge D. DemetriCorresponding
Harvard University, Dana-Farber Cancer Institute
- PRPeter Reichardt
Helios Hospital Bad Saarow
- YKYoon‐Koo Kang
Asan Medical Center, Ulsan College, University of Ulsan
- JBJean‐Yves Blay
Centre Léon Bérard, Université Claude Bernard Lyon 1
- PRPiotr Rutkowski
The Maria Sklodowska-Curie National Research Institute of Oncology
Topics & keywords
Topics
Keywords
- Regorafenib
- Medicine
- GiST
- Sunitinib
- Internal medicine
- Placebo
- Clinical endpoint
- Imatinib
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.